Cargando…

Therapeutic Cancer Vaccination With a Peptide Derived From the Calreticulin Exon 9 Mutations Induces Strong Cellular Immune Responses in Patients With CALR-Mutant Chronic Myeloproliferative Neoplasms

BACKGROUND: The calreticulin (CALR) exon 9 mutations that are identified in 20% of patients with Philadelphia chromosome negative chronic myeloproliferative neoplasms (MPN) generate immunogenic antigens. Thus, therapeutic cancer vaccination against mutant CALR could be a new treatment modality in CA...

Descripción completa

Detalles Bibliográficos
Autores principales:	Handlos Grauslund, Jacob, Holmström, Morten Orebo, Jørgensen, Nicolai Grønne, Klausen, Uffe, Weis-Banke, Stine Emilie, El Fassi, Daniel, Schöllkopf, Claudia, Clausen, Mette Borg, Gjerdrum, Lise Mette Rahbek, Breinholt, Marie Fredslund, Kjeldsen, Julie Westerlin, Hansen, Morten, Koschmieder, Steffen, Chatain, Nicolas, Novotny, Guy Wayne, Petersen, Jesper, Kjær, Lasse, Skov, Vibe, Met, Özcan, Svane, Inge Marie, Hasselbalch, Hans Carl, Andersen, Mads Hald
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7952976/ https://www.ncbi.nlm.nih.gov/pubmed/33718228 http://dx.doi.org/10.3389/fonc.2021.637420

Ejemplares similares

Therapeutic cancer vaccination against mutant calreticulin in myeloproliferative neoplasms induces expansion of specific T cells in the periphery but specific T cells fail to enrich in the bone marrow
por: Holmström, Morten Orebo, et al.
Publicado: (2023)

Novel Strategies for Peptide-Based Vaccines in Hematological Malignancies
por: Klausen, Uffe, et al.
Publicado: (2018)

Peptide Vaccination Against PD-L1 With IO103 a Novel Immune Modulatory Vaccine in Multiple Myeloma: A Phase I First-in-Human Trial
por: Jørgensen, Nicolai Grønne, et al.
Publicado: (2020)

Anti-PD-L1/PD-L2 therapeutic vaccination in untreated chronic lymphocytic leukemia patients with unmutated IgHV
por: Klausen, Uffe, et al.
Publicado: (2022)

An arginase1- and PD-L1-derived peptide-based vaccine for myeloproliferative neoplasms: A first-in-man clinical trial
por: Grauslund, Jacob Handlos, et al.
Publicado: (2023)

Cancer Immune Therapy for Philadelphia Chromosome-Negative Chronic Myeloproliferative Neoplasms
por: Holmström, Morten Orebo, et al.
Publicado: (2020)

Vaccination against PD-L1 with IO103 a Novel Immune Modulatory Vaccine in Basal Cell Carcinoma: A Phase IIa Study
por: Jørgensen, Nicolai Grønne, et al.
Publicado: (2021)

Differential Dynamics of CALR Mutant Allele Burden in Myeloproliferative Neoplasms during Interferon Alfa Treatment
por: Kjær, Lasse, et al.
Publicado: (2016)

High frequencies of circulating memory T cells specific for calreticulin exon 9 mutations in healthy individuals
por: Holmström, Morten O., et al.
Publicado: (2019)

The real-world outcomes of multiple myeloma patients treated with daratumumab
por: Szabo, Agoston Gyula, et al.
Publicado: (2021)

Revisiting Circulating Extracellular Matrix Fragments as Disease Markers in Myelofibrosis and Related Neoplasms
por: Hasselbalch, Hans Carl, et al.
Publicado: (2023)

Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?
por: Hasselbalch, Hans Carl, et al.
Publicado: (2018)

Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis
por: Kjær, Lasse, et al.
Publicado: (2023)

Healthy Donors Harbor Memory T Cell Responses to RAS Neo-Antigens
por: Holmström, Morten Orebo, et al.
Publicado: (2020)

P1004: ACTIVATING MUTATIONS IN JAK2 AND CALR DIFFERENTIALLY AFFECT INTRACELLULAR CALCIUM LEVELS AND CALCIUM FLUX
por: Bhuria, Vikas, et al.
Publicado: (2023)

Calreticulin (CALR)-induced activation of NF-ĸB signaling pathway boosts lung cancer cell proliferation
por: Gao, Fangfang, et al.
Publicado: (2022)

A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma
por: Kjeldsen, Julie Westerlin, et al.
Publicado: (2021)

Author Correction: A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma
por: Kjeldsen, Julie Westerlin, et al.
Publicado: (2022)

Calreticulin-mutant proteins induce megakaryocytic signaling to transform hematopoietic cells and undergo accelerated degradation and Golgi-mediated secretion
por: Han, Lijuan, et al.
Publicado: (2016)

The metabolic enzyme arginase-2 is a potential target for novel immune modulatory vaccines
por: Weis-Banke, Stine Emilie, et al.
Publicado: (2020)

Myocardial Infarction as an Initial Presentation of Essential Thrombocythemia With Calreticulin (CALR) Mutation (None Type 1, None Type 2)
por: Afana, Mohammad, et al.
Publicado: (2023)

P988: MUTANT CALRETICULIN AND JAK2V617F DRIVER MUTATIONS INDUCE DISTINCT MITOTIC DEFECTS IN MYELOPROLIFERATIVE NEOPLASMS
por: Holl, Kristin, et al.
Publicado: (2023)

Patients With Myeloproliferative Neoplasms Harbor High Frequencies of CD8 T Cell-Platelet Aggregates Associated With T Cell Suppression
por: Carnaz Simões, Ana Micaela, et al.
Publicado: (2022)

Corrigendum: Patients with myeloproliferative neoplasms harbor high frequencies of CD8 T cell-platelet aggregates associated with T cell suppression
por: Simões, Ana Micaela Carnaz, et al.
Publicado: (2022)

CALR frameshift mutations in MPN patient-derived iPSCs accelerate maturation of megakaryocytes
por: Olschok, Kathrin, et al.
Publicado: (2021)

Arginase-2-specific cytotoxic T cells specifically recognize functional regulatory T cells
por: Weis-Banke, Stine Emilie, et al.
Publicado: (2022)

Peptide vaccination activating Galectin-3-specific T cells offers a novel means to target Galectin-3-expressing cells in the tumor microenvironment
por: Bendtsen, Simone Kloch, et al.
Publicado: (2022)

TP53 Gene Status Affects Survival in Advanced Mycosis Fungoides
por: Wooler, Gitte, et al.
Publicado: (2016)

Calreticulin Ins5 and Del52 mutations impair unfolded protein and oxidative stress responses in K562 cells expressing CALR mutants
por: Salati, Simona, et al.
Publicado: (2019)

First in man study: Bcl-Xl_42-CAF(®)09b vaccines in patients with locally advanced prostate cancer
por: Mørk, Sofie Kirial, et al.
Publicado: (2023)

The telomerase inhibitor imetelstat differentially targets JAK2V617F versus CALR mutant myeloproliferative neoplasm cells and inhibits JAK-STAT signaling
por: Olschok, Kathrin, et al.
Publicado: (2023)

P1008: THE TELOMERASE INHIBITOR IMETELSTAT DIFFERENTIALLY TARGETS JAK2V617F- VERSUS CALR-MUTANT MYELOPROLIFERATIVE NEOPLASM CELLS AND INHIBITS JAK-STAT SIGNALING
por: Olschok, Kathrin, et al.
Publicado: (2023)

Pre-existing TGF-β-specific T-cell immunity in patients with pancreatic cancer predicts survival after checkpoint inhibitors combined with radiotherapy
por: Mortensen, Rasmus Erik Johansson, et al.
Publicado: (2023)

Production and Characterization of Peptide Antibodies to the C-Terminal of Frameshifted Calreticulin Associated with Myeloproliferative Diseases
por: Mughal, Farah Perveen, et al.
Publicado: (2022)

Ubiquitin-specific protease 2 decreases p53-dependent apoptosis in cutaneous T-cell lymphoma
por: Wei, Tianling, et al.
Publicado: (2016)

BRAF(V600E) Expression Is Homogenous and Associated with Nonrecurrent Disease and Better Survival in Primary Melanoma
por: Naimy, Soraya, et al.
Publicado: (2023)

Orbital precursor B-lymphoblastic lymphoma involving the extraocular muscles in a 56-year-old male and a review of the literature
por: Ejstrup, Rasmus, et al.
Publicado: (2019)

Gene Expression Linked to Reepithelialization of Human Skin Wounds
por: Ågren, Magnus S., et al.
Publicado: (2022)

Mice with Calr mutations homologous to human CALR mutations only exhibit mild thrombocytosis
por: Shide, Kotaro, et al.
Publicado: (2019)

JAK2V617F mutation is highly prevalent in patients with ischemic stroke: a case-control study
por: Kristiansen, Marie Hvelplund, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_1qicpdv5888ft1pe0st618d5ti